← Leaderboards
Joya Chandra
Mayo Clinic Coll Of Medicine, Rochester
$4,975,594
Attributed
$6,642,000
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $993.5K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,642,000 · 10
By mechanism
TL1$1,556,660 · 1
R01$1,295,012 · 1
T32$1,058,369 · 2
R21$892,625 · 2
R25$717,784 · 1
R33$701,480 · 1
Top collaborators
- Jeffrey A Frost6 shared
- Mark T Bedford3 shared
- David G. Johnson1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMutationIn VitroIn VivoProgramsPathway InteractionsResistanceResponseTexasModalityResearch PersonnelDesignProteinsLinkBinding SitesOncogenesTherapeutic TargetCell GrowthSignal TransductionPhosphotransferasesEpigenetic ProcessGrowthBaseBiological Markers
Grant awards (24)
CTSA Postdoctoral T32 at the University of Texas Health Science Center at Houston$267,040
T32 · FY2025 · TR
CTSA Predoctoral T32 at the University of Texas Health Science Center at Houston$266,535
T32 · FY2025 · TR
MD Anderson Summer Program in Cancer Research (SPCR)$201,799
R25 · FY2025 · CA · contact PI
CTSA Predoctoral T32 at the University of Texas Health Science Center at Houston$265,752
T32 · FY2024 · TR
CTSA Postdoctoral T32 at the University of Texas Health Science Center at Houston$259,042
T32 · FY2024 · TR
NRSA Training Core$801,484
TL1 · FY2023 · TR
MD Anderson Science Park Summer Program in Cancer Research SPCR$192,025
R25 · FY2023 · CA · contact PI
NRSA Training Core$755,176
TL1 · FY2022 · TR
MD Anderson Science Park Summer Program in Cancer Research SPCR$141,655
R25 · FY2022 · CA · contact PI
Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma$365,801
R33 · FY2021 · NS · contact PI
Defining and leveraging nutritional and circadian dependencies to augment acute leukemia therapy$198,750
R21 · FY2021 · NR · contact PI
MD Anderson Science Park Summer Program in Cancer Research SPCR$182,305
R25 · FY2021 · CA
Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma$335,679
R33 · FY2020 · NS · contact PI
Defining and leveraging nutritional and circadian dependencies to augment acute leukemia therapy$253,875
R21 · FY2020 · NR · contact PI
Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma$333,682
R61 · FY2019 · NS · contact PI
Preclinical evaluation of a novel combinatory epigenetics based therapy for glioblastoma$240,000
R21 · FY2016 · NS · contact PI
Preclinical evaluation of a novel combinatory epigenetics based therapy for glioblastoma$200,000
R21 · FY2015 · NS · contact PI
Role of Redox Dependent Signaling in Leukemia$292,600
R01 · FY2010 · CA · contact PI
Role of Redox Dependent Signaling in Leukemia$292,600
R01 · FY2009 · CA · contact PI
Role of Redox Dependent Signaling in Leukemia$124,612
R01 · FY2009 · CA · contact PI
Role of Redox Dependent Signaling in Leukemia$292,600
R01 · FY2008 · CA · contact PI
Role of Redox Dependent Signaling in Leukemia$292,600
R01 · FY2007 · CA · contact PI
Mechanism of action of a novel tyrosine kinase inhibitor$46,192
F32 · FY2002 · CA
Mechanism of action of a novel tyrosine kinase inhibitor$40,196
F32 · FY2001 · CA